Alignment Healthcare earnings release, July 30, 2026

Alignment Healthcare, Inc. (ALHC) · Form 8-K, Item 2.02 · Filed · SEC filing

Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics

Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year

Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 members

Raises the midpoint of all full-year guidance metrics: membership, revenue, adjusted gross profit and adjusted EBITDA

ORANGE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today reported financial results for its second quarter ended June 30, 2026.

“Our second quarter results underscore the strength of our purpose-built Medicare Advantage platform and place us in a strong position to deliver upon our full-year objectives," said John Kao, chairman and CEO. “We are continuing to realize the benefits of ongoing investments we have made across our clinical model, AI-enabled capabilities and operational infrastructure. These financial results are a reflection of how we are delivering for our seniors and demonstrate that better outcomes, stronger member experiences and sustainable profitable growth can all go hand in hand."

Second Quarter 2026 Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended

June 30, 2025.

Health plan membership at the end of the quarter was approximately 294,100, up 31.5% year-over-year

Total revenue was $1,335.6 million, up 31.6% year-over-year

Adjusted gross profit* was $182.9 million, up 35.3% year-over-year, and income from operations was $42.1 million

Adjusted gross profit excludes depreciation and amortization of $7.9 million and selling, general, and administrative expenses of $131.0 million (which includes $16.3 million of equity-based compensation). Adjusted gross profit also excludes $1.9 million of equity-based compensation recorded within medical expenses

Medical benefits ratio based on adjusted gross profit was 86.3%, an improvement of approximately 40 basis points year-over-year

Adjusted EBITDA* of $68.1 million represented an adjusted EBITDA margin of 5.1% and grew 48.4% year-over-year, while net income was $36.6 million, compared to $15.7 million the year prior

* Please see "Second Quarter 2026 Non-GAAP Reconciliation Tables" below for more information on the non-GAAP financial measures reported here as supplemental information.

Outlook for Third Quarter and Fiscal Year 2026

Second Quarter 2026 Non-GAAP Reconciliation Tables

Adjusted Gross Profit

Financial statements

Income Statement

Three Months Ending September 30, 2026 — Outlook for Third Quarter and Fiscal Year 2026 (in millions)

Three Months Ending September 30, 2026 – LowThree Months Ending September 30, 2026 – HighTwelve Months Ending December 31, 2026 – LowTwelve Months Ending December 31, 2026 – High
Health Plan Membership295,500297,500298,000301,000
Revenue1,3001,3205,1955,225
Adjusted Gross Profit(1)148158630650
Adjusted EBITDA(1)2030145163

Income Statement

Three Months Ended June 30, — is reconciled as follows: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
(dollars in thousands)Income from operations42,10022,74857,60317,355
Add back:Equity-based compensation (medical expenses)1,8931,5943,3042,746
Add back:Depreciation (medical expenses)3332666
Add back:Depreciation and amortization(2)7,8547,00315,69314,597
Add back:Selling, general, and administrative expenses131,003103,797252,141207,628
Add back:Total add back140,753112,427271,164225,037
Add back:Adjusted gross profit182,853135,175328,767242,392
Add back:(1) Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses. (2) Amortization expense for the six months ended June 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended June 30, 2025.(1) Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses. (2) Amortization expense for the six months ended June 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended June 30, 2025.(1) Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses. (2) Amortization expense for the six months ended June 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended June 30, 2025.(1) Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses. (2) Amortization expense for the six months ended June 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended June 30, 2025.(1) Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses. (2) Amortization expense for the six months ended June 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended June 30, 2025.

Income Statement

Three Months Ended June 30, — is reconciled as follows: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
(dollars in thousands)Net income36,56015,65347,9766,299
(dollars in thousands)Less: Net loss attributable to noncontrolling interest14254
Adjustments:Interest expense4,2753,9508,3377,900
Adjustments:Depreciation and amortization(2)7,8577,03615,71914,663
Adjustments:Income tax expense1,2663,2241,2913,245
Adjustments:Equity-based compensation(3)18,17415,55332,19332,740
Adjustments:Litigation costs(4)145554811,062
Adjustments:Gain on sale of property and equipment-1-72-1-72
Adjustments:Adjusted EBITDA68,14545,913105,99666,091

Income Statement (in thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenues:Earned premiums1,326,6251,006,2032,553,1911,924,246
Revenues:Other9,0089,08517,63917,974
Revenues:Total revenues1,335,6331,015,2882,570,8301,942,220
Expenses:Medical expenses1,154,676881,7402,245,3931,702,640
Expenses:Selling, general, and administrative expenses131,003103,797252,141207,628
Expenses:Depreciation and amortization7,8547,00315,69314,597
Expenses:Total expenses1,293,533992,5402,513,2271,924,865
Expenses:Income from operations42,10022,74857,60317,355
Other expenses:Interest expense4,2753,9508,3377,900
Other expenses:Other income, net-1-79-1-89
Other expenses:Total other expense4,2743,8718,3367,811
Other expenses:Income before income taxes37,82618,87749,2679,544
Other expenses:Provision for income taxes1,2663,2241,2913,245
Other expenses:Net income36,56015,65347,9766,299
Other expenses:Less: Net loss attributable to noncontrolling interest14254

Balance Sheet (in thousands, except par value and share amounts)

June 30, 2026December 31, 2025
Current Assets:Cash and cash equivalents693,453575,817
Current Assets:Accounts receivable (less allowance for credit losses of $265 at June 30, 2026 and $833 at December 31, 2025)296,893253,207
Current Assets:Investments - current8,25828,413
Current Assets:Prepaid expenses and other current assets161,84594,140
Current Assets:Total current assets1,160,449951,577
Current Assets:Property and equipment, net66,21164,251
Current Assets:Right of use asset, net7,3047,019
Current Assets:Goodwill32,06032,060
Current Assets:Intangible assets, net4,5504,550
Current Assets:Other assets8,4646,329
Current Assets:Total assets1,279,0381,065,786
Current Liabilities:Medical expenses payable612,748474,569
Current Liabilities:Accounts payable and accrued expenses32,27033,284
Current Liabilities:Accrued compensation38,38949,013
Current Liabilities:Total current liabilities683,407556,866
Current Liabilities:Long-term debt, net of debt issuance costs324,056323,176
Current Liabilities:Long-term portion of lease liabilities6,4446,467
Current Liabilities:Total liabilities1,013,907886,509
Stockholders' Equity:Common stock, $0.001 par value; 1,000,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 207,178,193 and 204,153,619 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively207205
Stockholders' Equity:Additional paid-in capital1,225,9651,188,089
Stockholders' Equity:Accumulated deficit-961,041-1,009,017
Stockholders' Equity:Total stockholders' equity265,131179,277
Stockholders' Equity:Total liabilities and stockholders' equity1,279,0381,065,786

Cash Flow (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating Activities:Net income47,9766,299
Adjustments to reconcile net income to net cash provided by operating activities:Provision for credit loss265262
Adjustments to reconcile net income to net cash provided by operating activities:Gain on sale of property and equipment-1-72
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization15,71914,663
Adjustments to reconcile net income to net cash provided by operating activities:Amortization-investment discount-350-731
Adjustments to reconcile net income to net cash provided by operating activities:Amortization-debt issuance costs1,147881
Adjustments to reconcile net income to net cash provided by operating activities:Equity-based compensation32,19332,740
Adjustments to reconcile net income to net cash provided by operating activities:Non-cash lease expense929246
Changes in operating assets and liabilities:Accounts receivable-43,951-129,259
Changes in operating assets and liabilities:Prepaid expenses and other current assets-67,705-56,333
Changes in operating assets and liabilities:Other assets11-52
Changes in operating assets and liabilities:Medical expenses payable138,179165,366
Changes in operating assets and liabilities:Accounts payable and accrued expenses-1,3248,631
Changes in operating assets and liabilities:Accrued compensation-10,6243,085
Changes in operating assets and liabilities:Lease liabilities-1,09620
Changes in operating assets and liabilities:Net cash provided by operating activities111,36845,746
Investing Activities:Purchase of investments-16,835-35,001
Investing Activities:Sale of property and equipment75
Investing Activities:Maturities of investments37,34039,990
Investing Activities:Sale of business1,065
Investing Activities:Acquisition of property and equipment-17,509-16,255
Investing Activities:Net cash provided by (used in) investing activities2,996-10,126
Financing Activities:Debt issuance costs-2,397-26
Financing Activities:Proceeds from stock option exercises5,6851,823
Financing Activities:Net cash provided by financing activities3,2881,797
Financing Activities:Net increase in cash117,65237,417
Financing Activities:Cash, cash equivalents and restricted cash at beginning of period577,937434,942
Financing Activities:Cash, cash equivalents and restricted cash at end of period695,589472,359
Supplemental disclosure of cash flow information:Cash paid for interest7,0136,740
Supplemental non-cash investing and financing activities:Acquisition of property in accounts payable128117
Full release

(1) is reconciled as follows:

Adjusted EBITDA

(1) is reconciled as follows:

Conference Call Details

The company will host a conference call at 5 p.m. EDT today to discuss these results and management’s outlook for future financial and operational performance. A live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: https://edge.media-server.com/mmc/p/wpvyxfni. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web links, and will remain available for approximately 12 months.

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for the quarter ending September 30, 2026, and year ending Dec. 31, 2026. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to maintain a high rating for our plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor, including potential federal reductions in MA funding; changes in laws and regulations applicable to our business model; risks related to our indebtedness; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; and the impact of shortages of qualified personnel and related increases in our labor costs. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and the other periodic reports we file with the SEC. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total above:

Non-GAAP Financial Measures

Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors. To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following non-GAAP measures: Medical Benefits Ratio, Adjusted EBITDA and Adjusted Gross Profit as these are performance measures that our management uses to assess our operating performance. Because these measures facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on sale of property and equipment, and equity-based compensation expense.

Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA in lieu of net income (loss), which is the most directly comparable financial measure calculated in accordance with GAAP.

Our use of the term Adjusted EBITDA may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.

Medical Benefits Ratio (MBR)

We calculate our MBR by dividing total medical expenses, excluding depreciation, and medical equity-based compensation, by total revenues in a given period.

Adjusted Gross Profit

Adjusted gross profit is a non-GAAP financial measure that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses.

Adjusted gross profit should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of adjusted gross profit in lieu of income (loss) from operations, which is the most directly comparable financial measure calculated in accordance with GAAP.

Our use of the term adjusted gross profit may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.

Investor Contact

Harrison Zhuo hzhuo@ahcusa.com

Media Contact

Jerry Slowey publicrelations@ahcusa.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Alignment Healthcare earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.